Characteristics and Early Predictors of Intensive Care Unit Admission among COVID-19 Patients in Qatar

Abuyousef, Safae; Alnaimi, Shaikha; Omar, Nabil E.; Elajez, Reem; Elmekaty, Eman; Arafa, Eisa; Barazi, Raja; Ghasoub, Rola; Rahhal, Ala; Hamou, Fatima; Al-Amri, Maha; Karawia, Ahmed; Ajaj, Fatima; Alkhawaja, Raja; Kardousha, Ahmed; Awaisu, Ahmed; Abou‐Ali, Adel; Khatib, Mahalaqua Nazli; Aboukamar, Mohamed; Al-Hail, Moza

doi:10.1016/j.ijid.2021.12.062

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of invasive mechanical ventilation was about 50% among COVID-19 patients in Qatar in 2020. [ 24 ] Assuming the rate of invasive mechanical ventilation is about 50% in the control arm, a minimum sample size of 190 patients will provide 80% power to detect a relative risk reduction of approximately 40% and absolute risk reduction of 20% in the intervention group. To account for 20% dropout rate, the estimated sample size would be 230 patients randomized in 1:1 ratio (115: 115).…”

Section: Methods and Analysismentioning

confidence: 99%

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

et al. 2022

View full text Add to dashboard Cite

Introduction: Colchicine acts upstream in the cytokines cascade by inhibiting the nod-like receptor protein 3 (NLRP3) inflammasome while interleukin 6 (IL-6) receptor antagonists, such as tocilizumab, block the end result of the cytokines cascade. Hence, adding colchicine to tocilizumab with the aim of blocking the early and end products of the cytokines cascade, might reduce the risk of developing cytokine storm. Methods and analysis: We aim to conduct an open-label randomized controlled trial to evaluate the efficacy and safety of adding colchicine to tocilizumab among patients with severe COVID-19 pneumonia to reduce the rate of invasive mechanical ventilation and mortality. We will include patients with severe COVID-19 pneumonia who received tocilizumab according to our local guidelines. Enrolled patients will be then randomized in 1:1 to colchicine versus no colchicine. Patients will be followed up for 30 days. The primary outcome is the rate of invasive mechanical ventilation and will be determined using Cox proportional hazard model. Discussion: Given colchicine’s ease of use, low cost, good safety profile, and having different anti-inflammatory mechanism of action than other IL-6 blockade, colchicine might serve as a potential anti-inflammatory agent among patients with severe COVID-19 pneumonia. This study will provide valuable insights on the use of colchicine in severe COVID-19 when added to IL-6 antagonists. Ethics and dissemination: The Medical Research Center and Institutional Review Board at Hamad Medical Corporation in Qatar approved the study protocol (MRC-01-21-299). Results of the analysis will be submitted for publication in a peer-reviewed journal.

show abstract

Section: Methods and Analysismentioning

confidence: 99%

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The available evidence suggests that patients with cancer are at a greater risk for severe disease, intensive care admission and mortality from COVID-19 infection compared to the general population. 23 The CDC declared that patients with certain medical conditions including cancer are liable to have severe illness from COVID-19. Such population are more likely to be hospitalized, need admission to the intensive care unit, require a ventilator, or die of the COVID-19 infection.…”

Section: Recommendations About Covid Vaccine In Cancer Populationmentioning

confidence: 99%

COVID-19 Vaccination in Cancer Patients: A Review Article

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) infection is caused by severe acute respiratory syndrome coronavirus 2. Adults with cancer are immunocompromised due to several causes including cancer itself and immunosuppressive therapy. Thus, cancer patients are more susceptible to develop COVID-19 infection. As COVID-19 vaccines became available, patients with cancer would benefit from receiving the vaccine. This article aims to review the recent evidences and recommendations about COVID-19 vaccination in cancer patients. Current guidelines recommend that patients with cancer should have the priority to receive the vaccine given their immunocompromised state. The timing of administration varies depending on cancer type and treatment. Generally, the vaccine should be given before starting the chemotherapy if possible or in between chemotherapy cycles and away from nadir phase. For other cancer treatments, it is recommended to give the vaccine when there is evidence of blood count recovery. In general, induction therapy and treatment for newly diagnosed patients should not be delayed for the vaccination purpose. It is noteworthy to mention that cancer patients especially those with hematologic malignancies might have absented or attenuated response to the vaccine due to their pathophysiological status. On the other hand, the current vaccine guidelines have been criticized for lacking evidence on some important topics that need to be addressed. Firstly, some vaccines have been granted an emergency use authorization, prior to the usual comprehensive safety and efficacy evaluation process. Secondly, specific populations including cancer patients were excluded from the approval trials for safety reasons. Finally, some recommendations regarding the COVID-19 vaccines are extrapolated from other vaccines studies. Further studies are required to fill these gaps and observational studies that include cancer patients are warranted to have a better understanding of the safety and efficacy of the vaccines in cancer patients.

show abstract

Characteristics and Early Predictors of Intensive Care Unit Admission among COVID-19 Patients in Qatar

Cited by 2 publications

References 0 publications

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

COVID-19 Vaccination in Cancer Patients: A Review Article

Contact Info

Product

Resources

About